{"id":905366,"date":"2025-11-04T16:03:38","date_gmt":"2025-11-04T21:03:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\/"},"modified":"2025-11-04T16:03:38","modified_gmt":"2025-11-04T21:03:38","slug":"lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\/","title":{"rendered":"Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent"},"content":{"rendered":"

\nData from Catalent\u2019s preclinical studies evaluating certepetide as a SMARTag\u00ae ADC payload showed both improved tumor selective penetration and efficacy
\n<\/h2>\n
\n

BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (\u201cLisata\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today highlighted positive preclinical data as announced by Lisata\u2019s licensing partner, Catalent, Inc. (\u201cCatalent\u201d), at the 16th<\/sup> Annual World ADC San Diego Conference, held November 3-6, 2025. Catalent\u2019s presentation included data demonstrating the positive impact of incorporating Lisata’s proprietary iRGD cyclic peptide product candidate, certepetide, and its analogs as a payload in Catalent\u2019s SMARTag\u00ae<\/sup> antibody-drug conjugate (\u201cADC\u201d) technology platform. Specifically, Catalent reported preclinical results showing that using certepetide as a non-cytotoxic ADC payload not only improved ADC efficacy but also broadened the distribution of the cytotoxic payload within the tumor microenvironment. A summary of these results can be found here<\/a> in the Company\u2019s latest corporate presentation.<\/p>\n

\u201cThis data is encouraging as it reinforces the large and growing body of evidence indicating that certepetide can enhance the targeting, penetration, and effectiveness of therapeutic agents – in this case, ADCs – in which it is chemically incorporated or co-administered,\u201d stated Kristen K. Buck, M.D., Executive Vice President of Research and Development and Chief Medical Officer of Lisata. \u201cADCs are one of the fastest growing and most exciting therapeutic categories in drug development. These results underscore our belief in the value of our licensing partnership with Catalent and supports our strategy of leveraging certepetide\u2019s unique mechanism to enhance the therapeutic potential across all modalities of treatments.\u201d<\/p>\n

Lisata licensed certepetide and its analogs to Catalent for use with its SMARTag\u00ae<\/sup> technology platform, as part of its Enhanced Conjugates innovations. Enhanced Conjugates are designed to amplify the effect of a cytotoxic payload by combining it with a non-cytotoxic payload, such as certepetide, with the goal of amplifying efficacy without compromising safety.<\/p>\n

\n About Certepetide<\/strong>\n <\/p>\n

Certepetide (formerly LSTA1), an\u00a0internalizing<\/em>\u00a0RGD (arginyl-glycyl-aspartic acid or iRGD), cyclic peptide product candidate, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered\u00a0anti-cancer drugs more efficiently penetrating and accumulating in the tumor. Certepetide also has been shown to modify the tumor microenvironment resulting in tumors which are more susceptible to immunotherapies. We and our collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. To date, certepetide has also demonstrated favorable safety, tolerability, and clinical activity in completed and ongoing clinical trials designed to test its ability to enhance the effectiveness of standard-of-care chemotherapy for pancreatic cancer. Lisata is exploring the potential of certepetide to enable a variety of treatment modalities to treat a range of solid tumors more effectively. Certepetide has been awarded Fast Track designation (U.S.) and Orphan Drug Designation for pancreatic cancer (U.S. and E.U.) as well as Orphan Drug Designation for glioma (U.S.) and osteosarcoma (U.S.). Additionally, certepetide has received Rare Pediatric Disease Designation for osteosarcoma (U.S.).<\/p>\n

\n About Lisata Therapeutics<\/strong>\n <\/p>\n

Lisata Therapeutics is a clinical-stage pharmaceutical company<\/u><\/a> dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata\u2019s cyclic peptide product candidate, certepetide<\/u><\/a>, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform<\/u><\/a>\u00ae<\/u><\/sup><\/a> technology<\/u><\/a>. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into the first quarter of 2027, encompassing anticipated data milestones from its ongoing clinical trials. For a comprehensive overview of certepetide’s mechanism of action, please view our informative short film<\/u><\/a>. For more information on the Company, please visit www.lisata.com<\/u><\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This communication contains \u201cforward-looking statements\u201d that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding the Company\u2019s clinical development programs are forward-looking statements. In addition, when or if used in this communication, the words \u201cmay,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cpredict\u201d and similar expressions and their variants, as they relate to Lisata or its management, may identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, the potential efficacy of certepetide as a treatment for patients with solid tumors; our beliefs about the potential uses and benefits of certepetide; the potential of the collaboration with Catalent to develop new treatment options; the expected expiration of our patents for certepetide; our ability to obtain patent term extension on our U.S. composition of matter patent; statements relating to Lisata\u2019s continued listing on the Nasdaq Capital Market; expectations regarding the capitalization, resources and ownership structure of Lisata; the approach Lisata is taking to discover and develop novel therapeutics; the adequacy of Lisata\u2019s capital to support its future operations and its ability to successfully initiate and complete clinical trials; and the difficulty in predicting the time and cost of development of Lisata\u2019s product candidates. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: results observed from preclinical or preliminary data are not necessarily indicative of final results and one or more of the clinical outcomes may materially change following more comprehensive reviews of the data and as more patient data becomes available, including the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations; the risk that product candidates that appeared promising in early research, preclinical studies, and clinical trials do not demonstrate safety and\/or efficacy in larger-scale or later clinical trials; the safety and efficacy of Lisata\u2019s product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in Lisata\u2019s clinical programs, Lisata\u2019s ability to finance its operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of Lisata\u2019s scientific studies, Lisata\u2019s ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in Lisata\u2019s markets, the ability of Lisata to protect its intellectual property rights; and legislative, regulatory, political and economic developments. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Lisata\u2019s Annual Report on Form 10-K filed with the SEC on February 27, 2025, and in other documents filed by Lisata with the Securities and Exchange Commission. Except as required by applicable law, Lisata undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events, or otherwise.<\/p>\n

\n Contact:<\/strong>\n <\/p>\n

Media and Investors:
Lisata Therapeutics
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone:\u00a0908-842-0084
Email: jmenditto@lisata.com<\/p>\n

This press release was published by a CLEAR\u00ae Verified individual.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Data from Catalent\u2019s preclinical studies evaluating certepetide as a SMARTag\u00ae ADC payload showed both improved tumor selective penetration and efficacy BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (\u201cLisata\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today highlighted positive preclinical data as announced by Lisata\u2019s licensing partner, Catalent, Inc. (\u201cCatalent\u201d), at the 16th Annual World ADC San Diego Conference, held November 3-6, 2025. Catalent\u2019s presentation included data demonstrating the positive impact of incorporating Lisata’s proprietary iRGD cyclic peptide product candidate, certepetide, and its analogs as a payload in Catalent\u2019s SMARTag\u00ae antibody-drug conjugate (\u201cADC\u201d) technology platform. Specifically, Catalent reported preclinical results … <\/p>\n

Continue reading “Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-905366","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Data from Catalent\u2019s preclinical studies evaluating certepetide as a SMARTag\u00ae ADC payload showed both improved tumor selective penetration and efficacy BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (\u201cLisata\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today highlighted positive preclinical data as announced by Lisata\u2019s licensing partner, Catalent, Inc. (\u201cCatalent\u201d), at the 16th Annual World ADC San Diego Conference, held November 3-6, 2025. Catalent\u2019s presentation included data demonstrating the positive impact of incorporating Lisata’s proprietary iRGD cyclic peptide product candidate, certepetide, and its analogs as a payload in Catalent\u2019s SMARTag\u00ae antibody-drug conjugate (\u201cADC\u201d) technology platform. Specifically, Catalent reported preclinical results … Continue reading "Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-04T21:03:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2ODUyNCM3MjQzNjQyIzIwMjExNTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent\",\"datePublished\":\"2025-11-04T21:03:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\\\/\"},\"wordCount\":1265,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2ODUyNCM3MjQzNjQyIzIwMjExNTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\\\/\",\"name\":\"Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2ODUyNCM3MjQzNjQyIzIwMjExNTI=\",\"datePublished\":\"2025-11-04T21:03:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2ODUyNCM3MjQzNjQyIzIwMjExNTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2ODUyNCM3MjQzNjQyIzIwMjExNTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\/","og_locale":"en_US","og_type":"article","og_title":"Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent - Market Newsdesk","og_description":"Data from Catalent\u2019s preclinical studies evaluating certepetide as a SMARTag\u00ae ADC payload showed both improved tumor selective penetration and efficacy BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (\u201cLisata\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today highlighted positive preclinical data as announced by Lisata\u2019s licensing partner, Catalent, Inc. (\u201cCatalent\u201d), at the 16th Annual World ADC San Diego Conference, held November 3-6, 2025. Catalent\u2019s presentation included data demonstrating the positive impact of incorporating Lisata’s proprietary iRGD cyclic peptide product candidate, certepetide, and its analogs as a payload in Catalent\u2019s SMARTag\u00ae antibody-drug conjugate (\u201cADC\u201d) technology platform. Specifically, Catalent reported preclinical results … Continue reading \"Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-04T21:03:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2ODUyNCM3MjQzNjQyIzIwMjExNTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent","datePublished":"2025-11-04T21:03:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\/"},"wordCount":1265,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2ODUyNCM3MjQzNjQyIzIwMjExNTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\/","name":"Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2ODUyNCM3MjQzNjQyIzIwMjExNTI=","datePublished":"2025-11-04T21:03:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2ODUyNCM3MjQzNjQyIzIwMjExNTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2ODUyNCM3MjQzNjQyIzIwMjExNTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lisata-therapeutics-highlights-positive-preclinical-data-of-certepetide-as-part-of-antibody-drug-conjugate-combinations-as-reported-by-licensing-partner-catalent\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/905366","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=905366"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/905366\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=905366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=905366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=905366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}